Refractory coeliac disease is a rare variant of glutensensitive enteropathy often associated with a poor prognosis and considerable morbidity. The patients present with severe malabsorption and nutritional impairment after initial or delayed failure of a strict glutenexclusion diet. A limited number of disorders mimicking coeliac disease also require to be excluded. Management may be difficult although a proportion of such patients may respond to anti-inflammatory or immunomodulatory therapy using corticosteroids and azathioprine or ciclosporin. In this issue of European Journal of Gastroenterology and Hepatology Turner et al. have reported a dramatic clinical effect of anti-tumour necrosis factor (anti-TNF) therapy in a patient with refractory coeliac disease. The disease was severe enough to necessitate inpatient admission and institution of intensive nutritional support before a trial of anti-TNF therapy using infliximab succeeded in inducing remission. A report by Gillett et al. [1] described a patient with refractory coeliac disease and selective IgA deficiency who, following a single infusion of infliximab, had an impressive and sustained response that persisted for 18 months with the addition of azathioprine maintenance therapy. The possibility of such effective rescue therapy in a group of very ill patients with limited therapeutic options merits further attention. The mechanism of induction of remission by anti-TNF treatment in refractory coeliac disease is at present a matter of speculation.
The impact of infliximab in the management of Crohn's disease has been considerable with impressive healing of mucosal ulcerations. Interestingly, the duration of response of several weeks following a single infusion suggests immunomodulatory effects rather than simply mopping up excess soluble TNF-a. The current explanation for this efficacy is that infliximab therapy results in a reduction in the excess of activated T lymphocytes that accumulate within the lamina propria in Crohn's disease through the induction of apoptosis after binding to transmembrane TNF. Infliximab is a chimeric IgG1 mono-clonal antibody and hence may also be involved in depletion of immune cells via complement mediated or antibody dependent natural killer cell mediated cytotoxicity. Infliximab induced programmed cell death has been demonstrated in Jurkat T cell-line, in lamina propria T lymphocytes of Crohn's disease patients as well as in peripheral blood monocytes [2,3]. Indeed, apoptosis has also recently been imaged in vivo in Crohn's disease patients following infliximab administration using technetium labelled annexin V. The proposed mechanism for apoptosis involves a significant increase in the bax/bcl-2 ratio [4] and consequent caspase 3 mediated programmed cell death [5] . In contrast, another anti-TNF biological agent, etanercept, p75 TNF receptor/Fc fusion protein, does not appear to be effective in Crohn's disease [6, 7] possibly due to poor stability of binding to transmembrane TNF compared to infliximab. Defective lymphocyte apoptosis was first demonstrated in a study that found that lamina propria lymphocytes isolated from areas of inflammation in Crohn's disease, ulcerative colitis and diverticular disease exhibited decreased CD2 induced apoptosis [8] . This resistance to apoptosis in Crohn's disease affects homeostastic balance between proliferation and immune cell death and results in the accumulation of lymphocytes in lamina propria. It remains a matter of debate whether this is a primary defect or simply secondary to the inflammatory milieu. The latter would account for the similar excess of lymphocytes in untreated or refractory coeliac disease. In addition, it remains speculative whether anti-TNF therapy may abrogate the wheat gliadin induced intestinal epithelial cell apoptosis. In Crohn's disease, the effect of infliximab on T-lymphocyte apoptosis is the reverse of that observed on inflamed intestinal epithelial cells.
DQ2 (a two-fold increase in allele frequency) further suggesting a potential role in coeliac disease. This polymorphism is associated with increased levels of TNF-a. Work into the pathogenesis of coeliac disease, in particular with T-cell clones [10] , confirms a central role of HLA DQ restricted T cells with a Th0/Th1 phenotype producing a characteristic pattern of cytokines with mainly interferon gamma as well as TNF-a production amongst others. Gliadin itself has also been demonstrated to stimulate TNF-a production from monocytes in humans. TNF-a is known to stimulate metalloproteinase production in the gut which contributes to damage by breakdown of the extra-cellular matrix. Histology of untreated coeliac tissue shows a preponderance of intra-epithelial lymphocytes. It is conceivable that, as in Crohn's disease, elimination of this excess of lymphocytes by the induction of apoptosis by anti-TNF treatment would induce remission by eradicating the inflammatory drive. In refractory coeliac disease intra-epithelial T-lymphocyte (IEL) phenotyping may reveal two distinct patterns, normal IELs or phenotypically immature IELs defined by a lack of characteristic T-lymphocyte markers. The latter, as well as monoclonal T cell receptor (TCR) g gene rearrangements, define a subgroup of refractory coeliac disease patients which overlaps with or develops enteropathy associated T cell lymphoma (EATL). The longevity of the remission and the impact of infliximab on the natural history of refractory coeliac disease is potentially important but careful immunophenotyping and TCR gene rearrangement studies are necessary to exclude this latter group of potentially cryptic EATL patients who are unlikely to respond to immunomodulatory therapy and may have a theoretically increased risk of lymphoma progression upon exposure to anti-TNF therapy.
The possibility that anti-TNF therapy may be effective in a particular subgroup(s) of refractory coeliac disease is intriguing, both from a therapeutic and pathogenetic aspect. One such potential group might be patients with both IgA deficiency and coeliac disease as they share an extended HLA haplotype which is associated with high TNF-a and low IL-10 levels [11, 12] . IL-10 is an antiinflammatory/regulatory cytokine that would normally suppress TNF-a production. In its absence this propensity for elevated levels of TNF-a may also predispose these patients to increased severity of their disease phenotype. Cytokine and genetic profiling of the two reported responders to infliximab and other potential patients may provide important clues as to the selection of candidate patients with refractory coeliac disease for anti-TNF therapy [13] . A caveat is the fact that refractory coeliac disease appears to represent a heterogeneous group of patients with the same histological end-point. This heterogeneity of patients therefore requires careful evaluation and exclusion of mimicking conditions/complications such as autoimmune enteropathy, Whipple's disease, ulcerative jejunitis and, in particular, lymphomatous transformation. An increasing wealth of evidence suggests a large proportion of refractory coeliac patients have a monoclonal IEL population as identified by TCR gene arrangement studies and may represent cryptic EATL. The risk of development of a lympho-proliferative complication in the context of anti-TNF treatment is an important concern. Further work is needed to evaluate the potential for anti-TNF therapy in coeliac disease and in particular in refractory coeliac disease and its subgroups. Meanwhile, after very careful evaluation including serology, small bowel imaging, push enteroscopy and wireless capsule endoscopy, HLA typing and detailed immunophenotyping of intestinal biopsies, a small subgroup of refractory coeliac disease patients may be considered ill enough to merit consideration of therapy with anti-TNF agents, especially if immunomodulatory therapy has failed. The outcome of such therapy requires careful documentation.
